Donation

Donate
Myeloma Minute

Case Study #1: Newly Diagnosed Multiple Myeloma, Diagnostic Criteria, Response, Extended Treatment Team, Shared Decision Making, Minimal Residual Disease

Joseph D. Tariman, PhD, ANP-BC
Beth Faiman, PhD , MSN, APRN-BC, AOCN®

download slides

 

How is the Black Swan Research Initiative Approaching Early Myeloma Development? 
How is the Black Swan Research Initiative Approaching Early Myeloma Development?
Read more
Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose
Read more
Previous Post
NLB 2016: Case #2, 3 Bone Health, Renal Health, 1+Prior Therapies, Immunotherapy, Clonal Evolution
Next Post
Robin Tuohy's testimony at CEPAC on Treatment Options for Relapsed and Refractory Myeloma.

Give Where Most Needed

Learn More